Log in to search using one of your social media accounts:

 

Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade

cyclophosphamide, stem cell transplant, nivolumab, ipilimumab, AML
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Publication date: Available online 12 September 2017 Source:Methods Author(s): Andreas K. Buck, Antje Stolzenburg, Heribert Hänscheid, Andreas Schirbel, Katharina Lückerath, Margret Schottelius, Hans-Jürgen Wester, Constantin Lapa The C-X-C chemokine receptor 4 (CXCR4) and its natural ligand CXCL12 are key factors in the process of cell migration, homing of hematopoietic stem cells to the bone marrow, and represent important mediators of angiogenesis and cell proliferation. The CXCR4/CXCL12 interplay can be disrupted by CXCR4 antagonists such as Plerixafor which are already in daily clinical use, i.e. for m...
Source: Methods - Category: Molecular Biology Source Type: research
This study aimed to evaluate potential disparities and barriers in access associated with this complex treatment modality.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Conclusion Among patients with relapsed CBF-AML, median survival was less than a year and half and the outcome was worse in patients with t (8; 21). Despite the relatively better outcomes, dedicated clinical trials are needed to improve the outcome in all patients with relapsed CBF-AML. Teaser Patients with CBF-AML who relapse have suboptimal outcomes. We retrospectively analyzed 92 CBF-AML patients at first relapse to identify factors associated with clinical outcome. Age, high white cell count, high bone marrow blast percentage and t(8;21) cytogenetic group were associated with worse prognosis. Our findings suggest that ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion A single-institutional retrospective analysis found no significant differences in outcomes using GCLAC or CLAG for rrAML patients, though formal comparisons should be performed in a randomized clinical trial. The cost of GCLAC was higher than CLAG which should be considered when evaluating salvage chemotherapy options.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 12 September 2017 Source:Methods Author(s): Andreas K. Buck, Antje Stolzenburg, Heribert Hänscheid, Andreas Schirbel, Katharina Lückerath, Margret Schottelius, Hans-Jürgen Wester, Constantin Lapa The C – X – C chemokine receptor 4 (CXCR4) and its natural ligand CXCL12 are key factors in the process of cell migration, homing of hematopoietic stem cells to the bone marrow, and represent important mediators of angiogenesis and cell proliferation. The CXCR4/CXCL12 interplay can be disrupted by CXCR4 antagonists such as Plerixafor which are already in daily clinical...
Source: Methods - Category: Molecular Biology Source Type: research
FLT3+ AML patients (prevalence 20%-30% in adult AML) often have rapid post-induction relapse, highlighting the need for new therapies. CPX-351 is a dual-drug liposomal encapsulation that delivers a synergistic ratio of cytarabine:daunorubicin. CPX-351 demonstrated significantly improved OS versus 7+3 in a phase 3 study in older adults with untreated high-risk AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a successful treatment modality for AML and MDS. Information on transplant outcomes among older patients is limited because of concern of adverse transplant-related mortality (TRM) and poor overall survival (OS).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Anthracyclines remain the cornerstone of therapy for a wide spectrum of malignancies and have markedly improved survival of patients with acute myeloid leukemia (AML). There is scarce data regarding the acute cardiotoxic effects of anthracyclines in AML patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Acute myeloid leukemia (AML) relapse after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) remains a significant cause of mortality and morbidity. Bone marrow Relapse is the most frequent presentation. Extra Medullary Relapse (EMR) is less common, the incidence of EMR in the literature ranges from 0.65% up to 41%.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Acute Myeloid Leukemia Source Type: research
The presence of minimal residual disease (MRD) at the time of Hematopoietic stem cell transplantation (HSCT) is well recognized as an adverse risk factor for poor outcomes in ALL and AML patients in morphologyc remission.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants | Yervoy